Overman, Michael J.

From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology

Raghav, K. P. S., Mahajan, S., Yao, J. C., Hobbs, B. P., Berry, D. A., Pentz, R. D., Tam, A., Hong, W. K., Ellis, L. M., Abbruzzese, J., et al. (2015) · Journal of Clinical Oncology

Meta-analysis and systematic reviewsPharmaceutical industry and healthcare

Cited by 59

Clinical and Functional Characterization of Atypical KRAS / NRAS Mutations in Metastatic Colorectal Cancer

Loree, J. M., Wang, Y., Syed, M. A., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A., Raymond, V. M., et al. (2021) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 43

Imaging-based biomarkers: changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy

Amer, A. M., Zaid, M., Chaudhury, B., Elganainy, D., Lee, Y., Wilke, C. T., Cloyd, J., Wang, H., Maitra, A., Wolff, R. A., et al. (2018) · Cancer

Pancreatic and Hepatic Oncology ResearchMRI in cancer diagnosis

Cited by 43

Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer

Morris, V. K., Overman, M. J., Lam, M., Parseghian, C. M., Johnson, B., Dasari, A., Raghav, K., Kee, B. K., Huey, R., Wolff, R. A., et al. (2022) · Cancer Research Communications

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 38

Development and validation of a gene signature classifier for consensus molecular subtyping of colorectal carcinoma in a CLIA-certified setting

Morris, J. S., Luthra, R., Liu, Y., Duose, D. Y., Lee, W., Reddy, N. G., Windham, J., Chen, H., Tong, Z., Zhang, B., et al. (2021) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 36

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.

Subbiah, V., Khawaja, M. R., Hong, D. S., Amini, B., Yungfang, J., Liu, H., Johnson, A., Schrock, A. B., Ali, S. M., Sun, J. X., et al. (2017) · JCI Insight

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 30

Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer

Randon, G., Intini, R., Cremolini, C., Elez, E., Overman, M. J., Lee, J., Manca, P., Bergamo, F., Pagani, F., Antista, M., et al. (2022) · European Journal of Cancer

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 24

Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer.

Lieu, C. H., Wolff, R. A., Eng, C., Overman, M. J., Henry, L., Coulson, R., Garrett, C. R., Abbruzzese, J. L., Gallick, G. E., & Kopetz, S. (2010) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 10

Aspirin use and PI3K mutations in metastatic colorectal cancer (mCRC).

Payapwattanawong, S., Osterlund, E., Vetere, G., Bent, A. H., Dasari, A., Kee, B. K., Parseghian, C., Willis, J., Shen, J. P. Y. C., Raghav, K. P. S., et al. (2026) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesInflammatory mediators and NSAID effects

Cited by 1